Vault-13

Deep Track Capital, LP

GREENWICH, CT · CIK 1856083 · 13F filing filed 2022-08-12

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$1.4bn reported value -6.6% vs Q1 2022
49positions
49.8%in top 10
6 new 22 added 11 reduced 6 sold out vs Q1 2022

Options: 1 call positions ($72.9m notional), 1 put positions ($2.1m notional) – listed below, not included above.

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 GLOBAL BLOOD THERAPEUTICS IN COM GBT GBT 3,646,690 $116.5m8.06% 8.06% AddedShares held: Q3 2021 —, Q4 2021 2.0m, Q1 2022 2.3m, Q2 2022 3.6m +1.3m +1,342,007 58.2%
2 NOVOCURE LTD ORD SHS NVCR NVCR 1,341,300 $93.2m6.45% 6.45% AddedShares held: Q3 2021 —, Q4 2021 550.0k, Q1 2022 1.0m, Q2 2022 1.3m +341.3k +341,300 34.1%
3 TRAVERE THERAPEUTICS INC COM TVTX TVTX 3,580,700 $86.8m6.00% 6.00% AddedShares held: Q3 2021 —, Q4 2021 2.5m, Q1 2022 3.1m, Q2 2022 3.6m +446.2k +446,197 14.2%
4 JAZZ PHARMACEUTICALS PLC SHS USD JAZZ JAZZ 500,000 $78.0m5.39% 5.39% ReducedShares held: Q3 2021 —, Q4 2021 500.0k, Q1 2022 517.1k, Q2 2022 500.0k -17.1k -17,051 -3.3%
5 KURA ONCOLOGY INC COM KURA KURA 3,697,969 $67.8m4.69% 4.69% AddedShares held: Q3 2021 —, Q4 2021 2.5m, Q1 2022 3.4m, Q2 2022 3.7m +286.0k +285,969 8.4%
6 MADRIGAL PHARMACEUTICALS INC COM MDGL MDGL 905,000 $64.8m4.48% 4.48% AddedShares held: Q3 2021 —, Q4 2021 500.0k, Q1 2022 786.0k, Q2 2022 905.0k +119.0k +119,000 15.1%
7 CHINOOK THERAPEUTICS INC COM ADRO ADRO 3,430,110 $60.0m4.15% 4.15% AddedShares held: Q3 2021 —, Q4 2021 2.4m, Q1 2022 3.0m, Q2 2022 3.4m +430.1k +430,110 14.3%
8 BIOMARIN PHARMACEUTICAL INC COM BMRN BMRN 654,365 $54.2m3.75% 3.75% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 654.4k
9 FATE THERAPEUTICS INC COM FATE FATE 2,018,005 $50.0m3.46% 3.46% AddedShares held: Q3 2021 —, Q4 2021 418.0k, Q1 2022 2.0m, Q2 2022 2.0m +18.0k +18,005 0.9%
10 BICYCLE THERAPEUTICS PLC SPONSORED ADS BCYC BCYC 2,900,000 $48.7m3.36% 3.36% AddedShares held: Q3 2021 —, Q4 2021 1.1m, Q1 2022 1.9m, Q2 2022 2.9m +1.0m +1,044,007 56.2%
11 BEAM THERAPEUTICS INC COM BEAM BEAM 1,250,000 $48.4m3.35% 3.35% AddedShares held: Q3 2021 —, Q4 2021 700.0k, Q1 2022 763.8k, Q2 2022 1.2m +486.2k +486,250 63.7%
12 IVERIC BIO INC COM OPHT OPHT 4,500,000 $43.3m2.99% 2.99% UnchangedShares held: Q3 2021 —, Q4 2021 4.0m, Q1 2022 4.5m, Q2 2022 4.5m
13 AGENUS INC COM NEW COM NEW 22,241,417 $43.1m2.98% 2.98% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 14.0m, Q2 2022 22.2m +8.2m +8,242,926 58.9%
14 ESPERION THERAPEUTICS INC NE COM ESPR ESPR 6,000,000 $38.2m2.64% 2.64% UnchangedShares held: Q3 2021 —, Q4 2021 5.6m, Q1 2022 6.0m, Q2 2022 6.0m
15 REPARE THERAPEUTICS INC COM RPTX RPTX 2,707,662 $37.9m2.62% 2.62% AddedShares held: Q3 2021 —, Q4 2021 2.1m, Q1 2022 2.7m, Q2 2022 2.7m +43.6k +43,645 1.6%
16 NUVATION BIO INC COM CL A NUVB NUVB 11,471,281 $37.2m2.57% 2.57% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 1.2m, Q2 2022 11.5m +10.3m +10,315,789 892.8%
17 IMMUNOVANT INC COM IMVT IMVT 9,455,000 $36.9m2.55% 2.55% AddedShares held: Q3 2021 —, Q4 2021 4.8m, Q1 2022 7.2m, Q2 2022 9.5m +2.2m +2,230,387 30.9%
18 NKARTA INC COM NKTX NKTX 2,814,844 $34.7m2.40% 2.40% AddedShares held: Q3 2021 —, Q4 2021 1.3m, Q1 2022 2.1m, Q2 2022 2.8m +701.0k +701,049 33.2%
19 NURIX THERAPEUTICS INC COM NRIX NRIX 2,436,164 $30.9m2.13% 2.13% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 2.4m
20 FORMA THERAPEUTICS HLDGS INC SHS SHS 4,050,000 $27.9m1.93% 1.93% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 1.7m, Q2 2022 4.0m +2.4m +2,390,294 144.0%
21 TRICIDA INC COM TCDA TCDA 2,732,117 $26.4m1.83% 1.83% AddedShares held: Q3 2021 —, Q4 2021 2.3m, Q1 2022 2.7m, Q2 2022 2.7m +79.4k +79,424 3.0%
22 ACADIA PHARMACEUTICALS INC COM ACAD ACAD 1,733,130 $24.4m1.69% 1.69% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 1.7m
23 DYNE THERAPEUTICS INC COM DYN DYN 3,500,000 $24.0m1.66% 1.66% UnchangedShares held: Q3 2021 —, Q4 2021 2.3m, Q1 2022 3.5m, Q2 2022 3.5m
24 4D MOLECULAR THERAPEUTICS IN COM FDMT FDMT 3,140,000 $21.9m1.52% 1.52% AddedShares held: Q3 2021 —, Q4 2021 1.9m, Q1 2022 2.4m, Q2 2022 3.1m +691.8k +691,800 28.3%
25 KEROS THERAPEUTICS INC COM KROS KROS 739,528 $20.4m1.41% 1.41% ReducedShares held: Q3 2021 —, Q4 2021 1.3m, Q1 2022 1.4m, Q2 2022 739.5k -640.8k -640,778 -46.4%
26 CRINETICS PHARMACEUTICALS IN COM CRNX CRNX 1,053,000 $19.6m1.36% 1.36% ReducedShares held: Q3 2021 —, Q4 2021 1.9m, Q1 2022 1.5m, Q2 2022 1.1m -488.7k -488,715 -31.7%
27 KALVISTA PHARMACEUTICALS INC COM KALV KALV 1,824,000 $17.9m1.24% 1.24% AddedShares held: Q3 2021 —, Q4 2021 1.5m, Q1 2022 1.7m, Q2 2022 1.8m +94.2k +94,243 5.5%
28 DICE THERAPEUTICS INC COM COM 1,042,900 $16.2m1.12% 1.12% ReducedShares held: Q3 2021 —, Q4 2021 1.3m, Q1 2022 1.2m, Q2 2022 1.0m -207.1k -207,100 -16.6%
29 INOZYME PHARMA INC COM COM 3,250,000 $15.5m1.07% 1.07% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 3.2m
30 SCHRODINGER INC COM SDGR SDGR 562,000 $14.8m1.03% 1.03% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 562.0k
31 ACUMEN PHARMACEUTICALS INC COM ABOS ABOS 3,100,000 $14.6m1.01% 1.01% AddedShares held: Q3 2021 —, Q4 2021 1.9m, Q1 2022 2.6m, Q2 2022 3.1m +500.9k +500,902 19.3%
32 ANAPTYSBIO INC COM ANAB ANAB 672,569 $13.7m0.94% 0.94% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 558.8k, Q2 2022 672.6k +113.8k +113,787 20.4%
33 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 1,170,290 $13.5m0.94% 0.94% UnchangedShares held: Q3 2021 —, Q4 2021 1.3m, Q1 2022 1.2m, Q2 2022 1.2m
34 ADICET BIO INC COM COM 892,028 $13.0m0.90% 0.90% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 892.0k
35 JOUNCE THERAPEUTICS INC COM JNCE JNCE 4,259,653 $12.9m0.89% 0.89% UnchangedShares held: Q3 2021 —, Q4 2021 4.0m, Q1 2022 4.3m, Q2 2022 4.3m
36 SILENCE THERAPEUTICS PLC ADS SLN SLN 951,580 $11.3m0.78% 0.78% UnchangedShares held: Q3 2021 —, Q4 2021 950.8k, Q1 2022 951.6k, Q2 2022 951.6k
37 RELMADA THERAPEUTICS INC COM RLMD RLMD 500,000 $9.5m0.66% 0.66% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 102.1k, Q2 2022 500.0k +397.9k +397,883 389.6%
38 HOOKIPA PHARMA INC COM COM 5,035,998 $8.2m0.57% 0.57% UnchangedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 5.0m, Q2 2022 5.0m
39 CENTURY THERAPEUTICS INC COM IPSC IPSC 924,641 $7.8m0.54% 0.54% ReducedShares held: Q3 2021 —, Q4 2021 250.0k, Q1 2022 926.5k, Q2 2022 924.6k -1.8k -1,828 -0.2%
40 MAGENTA THERAPEUTICS INC COM COM 5,359,000 $6.4m0.44% 0.44% UnchangedShares held: Q3 2021 —, Q4 2021 4.9m, Q1 2022 5.4m, Q2 2022 5.4m
41 ASSEMBLY BIOSCIENCES INC COM COM 3,000,000 $6.3m0.44% 0.44% UnchangedShares held: Q3 2021 —, Q4 2021 3.0m, Q1 2022 3.0m, Q2 2022 3.0m
42 SAGE THERAPEUTICS INC COM SAGE SAGE 171,800 $5.5m0.38% 0.38% ReducedShares held: Q3 2021 —, Q4 2021 500.0k, Q1 2022 675.0k, Q2 2022 171.8k -503.2k -503,200 -74.5%
43 PASSAGE BIO INC COM COM 2,320,000 $5.5m0.38% 0.38% ReducedShares held: Q3 2021 —, Q4 2021 3.2m, Q1 2022 3.4m, Q2 2022 2.3m -1.1m -1,055,000 -31.3%
44 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 499,400 $5.0m0.34% 0.34% UnchangedShares held: Q3 2021 —, Q4 2021 499.4k, Q1 2022 499.4k, Q2 2022 499.4k
45 FULCRUM THERAPEUTICS INC COM FULC FULC 1,000,000 $4.9m0.34% 0.34% AddedShares held: Q3 2021 —, Q4 2021 750.0k, Q1 2022 650.0k, Q2 2022 1.0m +350.0k +350,000 53.9%
46 GRITSTONE BIO INC COM GRTS GRTS 1,720,000 $4.2m0.29% 0.29% ReducedShares held: Q3 2021 —, Q4 2021 1.8m, Q1 2022 3.0m, Q2 2022 1.7m -1.3m -1,265,729 -42.4%
47 TENAYA THERAPEUTICS INC COM TNYA TNYA 483,836 $2.7m0.19% 0.19% ReducedShares held: Q3 2021 —, Q4 2021 762.3k, Q1 2022 546.9k, Q2 2022 483.8k -63.1k -63,087 -11.5%
48 ATYR PHARMA INC COM NEW ATYR ATYR 290,844 $823.0k0.06% 0.06% ReducedShares held: Q3 2021 —, Q4 2021 1.1m, Q1 2022 1.0m, Q2 2022 290.8k -737.7k -737,671 -71.7%
49 VIGIL NEUROSCIENCE INC COM VIGL VIGL 308,393 $796.0k0.06% 0.06% ReducedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 389.1k, Q2 2022 308.4k -80.7k -80,748 -20.8%

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
ALNYLAM PHARMACEUTICALS INC ALNY ALNY 463,663 $75.7m463.7k shares
ENANTA PHARMACEUTICALS INC ENTA ENTA 198,730 $14.1m198.7k shares
PROMETHEUS BIOSCIENCES INC 245,000 $9.3m245.0k shares
VERVE THERAPEUTICS INC 102,342 $2.3m102.3k shares
AUTOLUS THERAPEUTICS PLC AUTL AUTL 382,559 $1.6m382.6k shares
RAFAEL HLDGS INC RFL RFL 104,156 $261.0k104.2k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
ALNYLAM PHARMACEUTICALS INC ALNY · Call ALNYCall 499,900 $72.9m499.9k shares New
PROTAGONIST THERAPEUTICS INC PTGX · Put PTGXPut 260,500 $2.1m260.5k shares Added

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on. The largest 25 of 28.

CompanyTickerStakeChange ScheduleLast filed
LB PHARMACEUTICALS INC LBRX · 13D · filed 2026-02-10 LBRX 11.7%≈ $108.8m -3.2 pts 13D 2026-02-10
ALTIMMUNE INC ALT · 13G · filed 2026-04-30 ALT 10.0%≈ $59.0m new 13G 2026-04-30
PROMIS NEUROSCIENCES INC PMN · 13G · filed 2026-02-06 PMN 10.0%≈ $11.9m new 13G 2026-02-06
VERASTEM INC VSTM · 13G · filed 2025-11-21 VSTM 10.0%≈ $29.5m new 13G 2025-11-21
COMPASS PATHWAYS PLC CMPS · 13G · filed 2025-01-17 CMPS 10.0% new 13G 2025-01-17
RAPT THERAPEUTICS INC 13G · filed 2024-12-23 9.9% new 13G 2024-12-23
MOONLAKE IMMUNOTHERAPEUTICS MLTX · 13G · filed 2026-08-14 MLTX 9.7%≈ $155.7m +3.3 pts 13G 2026-08-14
OCULAR THERAPEUTIX INC OCUL · 13G · filed 2026-05-15 OCUL 9.5%≈ $204.7m +4.4 pts 13G 2026-05-15
MAZE THERAPEUTICS INC MAZE · 13G · filed 2025-08-14 MAZE 9.0%≈ $117.8m +2.1 pts 13G 2025-08-14
IMMUNIC INC 13G · filed 2026-03-04 8.7% new 13G 2026-03-04
ALECTOR INC ALEC · 13G · filed 2026-10-23 ALEC 8.6%≈ $21.3m new 13G 2026-10-23
TARSUS PHARMACEUTICALS INC TARS · 13G · filed 2026-05-15 TARS 8.5%≈ $226.6m +1.4 pts 13G 2026-05-15
X4 PHARMACEUTICALS INC XFOR · 13G · filed 2026-08-14 XFOR 8.3%≈ $37.6m -1.7 pts 13G 2026-08-14
CONTEXT THERAPEUTICS INC CNTX · 13G · filed 2025-05-15 CNTX 8.3%≈ $4.1m 13G 2025-05-15
HEMAB THERAPEUTICS HLDGS INC COAG · 13G · filed 2026-05-08 COAG 8.2%≈ $132.3m new 13G 2026-05-08
CORMEDIX INC CRMD · 13G · filed 2026-05-15 CRMD 7.9%≈ $49.3m +1.7 pts 13G 2026-05-15
NURIX THERAPEUTICS INC NRIX · 13G · filed 2026-08-14 NRIX 7.5%≈ $187.7m +1.3 pts 13G 2026-08-14
ATENTO S A ATTO · 13G · filed 2026-08-12 ATTO 7.5% new 13G 2026-08-12
CENTURY THERAPEUTICS INC IPSC · 13G · filed 2026-01-15 IPSC 7.3%≈ $33.0m new 13G 2026-01-15
ACLARIS THERAPEUTICS INC ACRS · 13G · filed 2026-03-17 ACRS 7.0%≈ $49.4m new 13G 2026-03-17
AVALO THERAPEUTICS INC AVTX · 13G · filed 2026-08-14 AVTX 6.9%≈ $66.7m +1.1 pts 13G 2026-08-14
MIND MEDICINE MINDMED INC 13G · filed 2025-11-14 6.9% -1.3 pts 13G 2025-11-14
ENGENE HOLDINGS INC 13G · filed 2025-11-18 6.7% +2.3 pts 13G 2025-11-18
BICARA THERAPEUTICS INC BCAX · 13G · filed 2026-05-15 BCAX 6.2%≈ $120.6m +1.2 pts 13G 2026-05-15
ALUMIS INC ALMS · 13G · filed 2026-04-07 ALMS 6.0%≈ $207.2m new 13G 2026-04-07